SCHEMBL2407217

SCHEMBL2407217

Cc1ccc(-c2nccnc2C(=O)N(CCc2c[nH]c3c(C)cccc23)CC2CC2)cc1C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR2 P21452 2/20 0.37
HTR2A P28223 1/20 0.36
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
BCHE P06276 2/20 0.33
MC4R P32245 1/20 0.33
MC5R P33032 1/20 0.33
MC3R P41968 1/20 0.33
MAPK14 Q16539 1/20 0.33
CDK4 P11802 3/20 0.33
CCND1 P24385 3/20 0.33
CDK2 P24941 2/20 0.33
OXTR P30559 2/20 0.32
AVPR1A P37288 2/20 0.32
ACHE P22303 1/20 0.32
SOS2 Q07890 1/20 0.31
SLC6A9 P48067 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2404868 0.93 MPO (0.38) TACR2BCHECDK4CCND1OXTR
SCHEMBL2406776 0.91 HTR6 (0.43) TACR2HTR2ABCHECDK4CCND1
SCHEMBL2406987 0.91 TACR2 (0.40) TACR2HTR2AMAPTSMN1; SMN2NPSR1
SCHEMBL1967482 0.89 TACR2 (0.48) TACR2BCHEMC4RMC5RMC3R
SCHEMBL2408351 0.89 CDK4 (0.40) TACR2HTR2AMAPTSMN1; SMN2NPSR1
SCHEMBL2409274 0.89 TACR2 (0.39) TACR2HTR2AMAPTSMN1; SMN2NPSR1
SCHEMBL2403278 0.87 TACR2 (0.35) TACR2HTR2AMAPTSMN1; SMN2NPSR1
SCHEMBL2404564 0.86 TACR2 (0.37) TACR2HTR2AMAPTSMN1; SMN2NPSR1
SCHEMBL2406004 0.85 TACR2 (0.39) TACR2HTR2AMAPTBCHEMC4R
SCHEMBL2410229 0.85 MTNR1A (0.41) TACR2HTR2AMAPTSMN1; SMN2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 US claimed
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES HCRTR2, HCRTR1, HRH3 TACR2 90/4885HTR2A 46/4885MAPT 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.